Bellicum Announces Data Presentations At The Annual Meetings Of The ASCO And The European Hematology Association

HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company was selected for a poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 3 – 7 in Chicago, IL.